CHGCF Chugai Pharmaceutical Co., Ltd. Forecast, Technical & Fundamental Analysis

CHGCF in -4.18% downward trend, falling for three consecutive days on October 17, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CHGCF declined for three days, in of 40 cases, the price declined further within the following month. The odds of a continued downward trend are .

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 30 cases where CHGCF's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

CHGCF broke above its upper Bollinger Band on October 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 06, 2025. You may want to consider a long position or call options on CHGCF as a result. In of 62 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CHGCF just turned positive on October 03, 2025. Looking at past instances where CHGCF's MACD turned positive, the stock continued to rise in of 33 cases over the following month. The odds of a continued upward trend are .

CHGCF moved above its 50-day moving average on October 02, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CHGCF crossed bullishly above the 50-day moving average on October 07, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CHGCF advanced for three days, in of 44 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CHGCF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.083) is normal, around the industry mean (9.785). P/E Ratio (30.531) is within average values for comparable stocks, (24.212). CHGCF's Projected Growth (PEG Ratio) (4.806) is slightly higher than the industry average of (2.012). Dividend Yield (0.015) settles around the average of (0.028) among similar stocks. CHGCF's P/S Ratio (10.091) is very high in comparison to the industry average of (3.527).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHGCF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock worse than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.